ABSTRACT
study showed that both patients with T2DM and their carers lose income, especially when the patients experience diabetic complications [5] .
According to the CODE-2 study, overall indirect costs of absenteeism related to diabetes in Italy amount to €234 million [6] .
According to international guidelines, the management of T2DM includes the implementation of a healthy lifestyle, the introduction of metformin, which has proved to be able to reduce the risk of diabetic complications and death, and the use of other pharmacological options, as most patients require the addition of a second oral antidiabetic drug [7] [8] [9] .
Vildagliptin is a dipeptidyl peptidase-4 (DPP -4) inhibitor that has proved to be effective in reducing glycated hemoglobin (HbA1c) without weight gain and with minimal hypoglycemia, when it is given as monotherapy or in combination with the most commonly prescribed classes of oral hypoglycemic drugs, including metformin [10, 11] . Both vildagliptin 
INTRODUCTION
European and US studies have shown that patients with type 2 diabetes mellitus (T2DM) account for 3-5% of the total population, but consume up to 15-20% of total healthcare resources [1] . According to the European CODE-2 (Costs of Diabetes in Europe-Type 2) study [2] , the reason for this is frequent hospitalizations due to diabetic complications, which account for more than half of the healthcare costs (55%) due to diabetes. The situation is alarming for healthcare budgets as the worldwide prevalence of T2DM is continually increasing: the World Health Organization (WHO) has estimated that it amounted to 171 million patients in 2000 and will more than double over 30 years, reaching 366 million in 2030 [3] .
Diabetes is associated also with indirect costs, as diabetic complications reduce the patient's ability to work, resulting in loss of productivity and need for social service support. The Centers for Disease Control in the US have estimated that patients with diabetes lose on average 8.3 days of work per year versus 1.7 days per year for patients without diabetes [4] , and a European data (HbA1c), patient satisfaction data (DTSQ status scores), resource utilization (Resources U t i l i z a t i o n Q u e s t i o n n a i r e o u t c o m e ) , exposure to the fixed combination, and study completion status.
The WPAI [14] is a six-item questionnaire aimed at evaluating the impact of a disease on absenteeism rate and work productivity over the last 7 days; it is completed by the patient. Four scores were derived from it: absenteeism (% work time missed due to ill health, calculated as Q2/[Q2+Q4]), activity impairment (% activity impairment due to ill health, calculated as Q6/10), work productivity score (% overall work impairment due to health, calculated as [Q2+Q4×Q5/10]/
[Q2+Q4]), presenteeism (% impairment while working due to health, calculated as Q5/10). However, considering the main study endpoint, presenteeism was not evaluated among the primary nor secondary variables, due to its lower impact on the NHS. For all the above scores, higher numbers indicate greater impairment and less productivity.
For the WPAI questionnaire, WPAI General Health (WPAI-GH) domains calculation, the following statements were adopted: if a patient declared not to be employed (Q1 = 0), the remaining items dealing with work aspects (i.e., Q2, Q3, Q4, and Q5) were considered as missing values. If a patient declared not to be employed (Q1 = 0) but even one item concerning work aspects (Q2, Q3, Q4, Q5) was compiled with a positive value >0, the patient was assumed to be employed (i.e., the Q1 answer was assumed to be 1). If a patient declared to be not employed or had Q1 missing value, and both Q2 and Q4 were = 0, the patient was assumed not to be employed (i.e., the Q1 answer was assumed to be 0). If a patient declared to be employed, the following consistency rules among work-answers were checked: Treatment Satisfaction Questionnaire (DTSQs), the change in anthropometric measurements and in glucose control (HbA1c) after 1 year of treatment, and the evaluation of resource utilization (Resources Utilization Questionnaire).
MATERIALS AND METHODS
The study was a prospective, observational, Out of the 140 patients who did not complete the study, 57 (5.5%) withdrew their informed consent and 83 (7.9%) were lost to follow-up.
Mean ± SD exposure to the fixed combination was 11.7 ± 1.1 months.
The patients were mostly Caucasian (98.6%); nearly all the remaining patients were Asian (1.1%). The population included patients of all ages, ranging from 28 to 88 years of age, but most of them were middle-aged (46-65 years; 62.1%) or elderly (>65 years; 30.6%); 60.9% were of working age, but only 36.6% were actually working.
Slightly more patients were male (57.7%).
On average, they had been diagnosed with T2DM 7.7 ± standard deviation (SD) 6.7 years earlier; most of the patients had been diagnosed no more than 10 years earlier (74.4%). More than 50% of the patients (52.8%) had concomitant diseases: the most common were vascular disorders (72.3%; mainly hypertension 70.8%), metabolism and nutrition disorders (42.8%, mainly dyslipidemia 19.2%, hypercholesterolemia 12.1%, and obesity 10.7%), and heart disease (12.7%, mainly ischemic heart disease 6.3%).
All the three WPAI domains improved significantly after 1 year of treatment. Mean activity impairment improved significantly by 40.6% (P < 0.0001). At baseline a total of 367 patients were actually working (36.6%), and could provide absenteeism and total work productivity data; after 1 year absenteeism improved significantly by 49.9% (P = 0.0076, n = 248) and total work productivity score improved significantly by 37.6% (P < 0.0001, n = 244). Major improvement was already recorded after 6 months of treatment (Fig. 1 Table 2 ).
The mean (SD) TTS score increased significantly by 30.2% (29.6 ± 5.6 vs. 22.8 ± 6.9; P < 0.0001) after 1 year. The proportion of patients who were very satisfied with treatment increased from baseline by 44.7%, those who perceived themselves as hyperglycemia-free or almost hyperglycemia-free by 37.9%, and those who perceived themselves as hypoglycemia-free or almost hypoglycemia-free by 15.2% (Fig. 2) .
A post-hoc analysis comparing activity impairment status (worsened, i.e., change vs. baseline >0; stable, i.e., change vs. baseline = 0; improved, i.e., change vs. baseline <0) with the perception of hypoglycemia (worsened, stable, improved) showed that there was a statistically significant association between stable and improved activity impairment and stable or improved perception of hypoglycemia (chi-square P < 0.0001). Activity impairment and perception A er 1 year of treatment the annual number of h per patient missed for the disease management decreased by 56% 11.7% of patients (n = 123) lost on average 501 h in the year before and 206 h during the 1-year follow-up The assessment of direct healthcare costs is lower also than in previous observational studies [29] . As the study did not consider the cost of drugs, it is not fully consistent with a previous assessment of the economic impact of the introduction of vildagliptin, both alone and in fixed combination with metformin, on healthcare expenditure for T2DM patients in Italy [30] . This assessment ascertained that the introduction of vildagliptin involved an increase in pharmaceutical costs that was offset by a reduction in the management costs of serious or severe adverse events (which were fewer as specified below and documented in the Periodic Safety Update Reports on metformin, vildagliptin) [31] and in therapeutic monitoring. Nevertheless, the outcome was that introduction of the fixed combination produced an overall increase in healthcare expenditure by 1.48%, a modest increase, but not no effect at all or even a reduction as this study 
